Compare SPOK & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPOK | IVVD |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.7M | 201.9M |
| IPO Year | 2004 | 2021 |
| Metric | SPOK | IVVD |
|---|---|---|
| Price | $10.66 | $0.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $14.00 | $8.75 |
| AVG Volume (30 Days) | 160.8K | ★ 4.4M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | 2.74 | ★ 79.02 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $139,708,000.00 | $53,426,000.00 |
| Revenue This Year | $1.70 | $61.57 |
| Revenue Next Year | N/A | $41.42 |
| P/E Ratio | $116.78 | ★ N/A |
| Revenue Growth | 1.49 | ★ 110.47 |
| 52 Week Low | $9.95 | $0.49 |
| 52 Week High | $19.31 | $3.07 |
| Indicator | SPOK | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 31.35 |
| Support Level | $10.26 | N/A |
| Resistance Level | $10.78 | $1.01 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 30.58 | 6.59 |
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.